A positive psychedelic depression Phase 3 topline reports in 2026.

A late-stage clinical trial testing a psychedelic treatment for depression is expected to share its headline results this year. This is the final hurdle before a company can ask regulators to approve the drug. If results are good, it could mean a new treatment option for people who haven't responded to antidepressants.

86% enrollment with topline due this year, plus convergent mechanistic data on synaptic plasticity. The biology and clinical signal align. Delay costs lives.